Inhibitex has added two corporate officers, one of whom is a former Glaxo executive who attended medical school at the University of North Carolina in Chapel Hill.

Seth V. Hetherington, who was most recently director and clinical matrix team leader in infectious diseases at Glaxo, was named vice president of clinical affairs and chief medical officer at Inhibitex.

The company also named David M. Wonnacott as vice president of quality and regulatory affairs.

“Dr. Hetherington’s rich experience in the clinical development of infectious disease products provides us with the leadership necessary to aggressively move products through clinical trials,” William D. Johnston, president and chief executive officer of Inhibitex, said in a statement.

Hetherington spent seven years at Glaxo. He received a B.S. from
Yale University, and his medical degree from the UNC. Hetherington trained at Chapel Hill and the University of Minnesota, and has had clinical appointments at UNC, the University of Tennessee, St. Jude Children’s Research Hospital in Memphis and Albany Medical College in New York.

Wonnacott joins Inhibitex from Aviron, Inc., (recently acquired
by MedImmune, Inc.) where he served as the vice president of
regulatory affairs.

Inhibitex, located in Atlanta, is a biopharmaceutical company
developing and commercializing antibody-based products for the treatment and prevention of staphylococcal and other bacterial and fungal infections.